CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Adjuvant Imatinib Treatment for 5 Years versus 3 Years in Patients with Ruptured Localized Gastrointestinal Stromal Tumor: A Retrospective Analysis
Sora Kang, Min-Hee Ryu, Yeong Hak Bang, Hyung-Don Kim, Hyung Eun Lee, Yoon-Koo Kang
Cancer Research and Treatment. 2022;54(4):1167-1174.   Published online 2011 December 6    DOI: https://doi.org/10.4143/crt.2021.1040

Excel Download

Adjuvant Imatinib Treatment for 5 Years versus 3 Years in Patients with Ruptured Localized Gastrointestinal Stromal Tumor: A Retrospective Analysis
Cancer Research and Treatment. 2022;54(4):1167-1174   Crossref logo
Link1 Link2 Link3

PCN78 OST-EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH IMATINIB MESYLATE IN PATIENTS AFTER RESECTION OF LOCALIZED PRIMARY GASTROINTESTINAL STROMAL TUMOR
Value in Health. 2010;13(7):A265-A266   Crossref logo
Link1 Link2

A Cost-Effectiveness Analysis of Three Years of Adjuvant Imatinib in Kit+ Gastrointestinal Stromal Tumors (GIST) in Greece
Annals of Oncology. 2012;23:ix236   Crossref logo
Link1 Link2

Benefit of imatinib adjuvant therapy for patients with intermediate risk gastrointestinal stromal tumor: a multi-center retrospective analysis in China
. 2019;   Crossref logo
Link1 Link2

Approval Summary: Imatinib Mesylate for One or Three Years in the Adjuvant Treatment of Gastrointestinal Stromal Tumors
The Oncologist. 2012;17(7):992-997   Crossref logo
Link1 Link2 Link3 Link4

Cost-Effectiveness of Three-Years of Adjuvant Imatinib in Gastrointestinal Stromal Tumors (GIST) in Canada
Annals of Oncology. 2012;23:ix235   Crossref logo
Link1 Link2

Appropriate durations of adjuvant imatinib in patients with high-risk gastrointestinal stromal tumor (GIST) the better choice, for the year 2010
Clinical Management Issues. 2015;5(4S):13-16   Crossref logo
Link1 Link2

Adjuvant and Neoadjuvant Treatment
Gastrointestinal Stromal Tumor. 2019;129-144   Crossref logo
Link1

PCN27 Clinical Benefit and Economic Impact of Three-Years of Adjuvant Imatinib in KIT+ Gastrointestinal Stromal Tumors (GIST)
Value in Health. 2012;15(4):A212   Crossref logo
Link1 Link2

Adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: a retrospective cohort study
Scientific Reports. 2017;7(1):   Crossref logo
Link1 Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.